Enflunib

恩氟尼布

Report date: 2024/07/18 15:42:37
NME

Base Information

Drug NameEnflunib
Drug Alias NameSH-1573
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIsocitrate dehydrogenase [NADP], mitochondrial inhibitors
TargetsIsocitrate dehydrogenase [NADP], mitochondrial
Therapy Area/IndicationsHematologic NeoplasmsLeukemia, Myeloid, AcuteLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesNanjing Sanhome Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNanjing Sanhome Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLeukemia, Myeloid, AcuteLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A